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The study objective was to determine the age associated medication adherence among low income type-
2 diabetes patients enrolled in Medicaid. This was a retrospective cohort study consisting of patients aged
18–44 years (n = 681), 45–64 years (n = 2327) and 65+ years (n = 161), respectively newly starting anti-
diabetic medication between July 2001 and June 2002. Medication adherence was measured as medica-
tion possession ratio using prescription reﬁll patterns. Multiple regression analyzes showed that
compared to age group 18–44 years, age groups 65+ and 44–64 years had signiﬁcantly higher adherence
rate by 13.4% and 12.5%, respectively. Better oral antidiabetic medication adherence was associated with
increased age.
 2010 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.1. Introduction
Diabetes is one of the major reasons for mortality and morbidity
in the U.S. In 2007, about 23.6 million people were suffering from
diabetes, making it the seventh cause of death nationally. Direct
and indirect medical costs estimated with diabetes were about
$116 and $58 billion, respectively [1–3]. It is a metabolic disorder,
and the root cause of many micro vascular and macro vascular
complications [4]. Studies have shown that an increase in the num-
ber of medications might present hurdles in adhering to OHDs in
case of patients who are elderly, socially deprived and have many
co-morbidities [4,5]. This paper examines the effect of starting a
new medication therapy on medication adherence of patients suf-
fering from type-2 diabetes.ellitus. Published by Elsevier Ltd.
: +1 734 615 8171.
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roject.
O2. Materials and methods
2.1. Study subjects
This was a retrospective cohort study, which used data of con-
tinuously eligible type-2 diabetes enrollees of the North Carolina
Medicaid program from July 1, 2000 to June 30, 2000 across age
groups 18–44 years, 45–64 years and 65+ years. Patients were
identiﬁed using at least 1 or more ICD-9 code (International Classi-
ﬁcation of Diseases, Ninth Revision (ICD-9), Clinical Modiﬁcation)
for type-2 diabetes (250.xx) and one NDC code (National Drug
Code) for antidiabetic medication. Patients on insulin therapy
alone and <18 years were excluded. Patients using monotherapy
and not having used any of the oral anti diabetic drugs like metfor-
min or sulphonylurea or TZD in the previous year were included
[3,6].
2.2. Adherence
The medication possession ratio (MPR) based on the Med-Total
approach by Steiner et al. was calculated as the days of antidiabetic
prescription supply dispensed divided by the number of days be-
tween these prescription reﬁlls [7]. The observation period began
with the ﬁrst date of dispensing within each year and ended as
the dispensing date of the last prescription [3,6].pen access under CC BY-NC-ND license.
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The natural logarithm of Medication possession ratio (MPR) was
the outcome variable, as the distribution of MPR was found to be
skewed (as determined by the Shapiro–Wilk test) [3,6].
*Outcome [ln(MPR)] = f (age indicator, treatment group indica-
tor, demographic and clinical confounders).
All the data analysis was conducted using the STATA software
(StataCorp LP, Texas).Table 2
Comparison of adherence rate between different age groups using multiple regression3. Results
Table 1 gives the descriptive characteristics of the study popu-
lation across different age groups. In the case of medication ther-
apy, metformin and sulphonylurea were used more by the age
group 18–44 years, whereas TZD was used more by the age group
65+ years. Medication adherence was highest for the age group 65+
years. People in the age group of 45–64 years had higher health-
care costs in year 1, and more co-morbidities.
Table 2 gives an OLS multiple log-linear regression was con-
ducted to measure the association between medication adherence
and patients’ information. Compared with age group 18–44, the
age group 45–64 and over 65 had higher adherence by 12.5% and
13.4%, respectively. Metformin and Tzd users had almost 34.5%
lower and 2.4% higher medication adherence, as compared to sul-
fonylurea users (p < 0.05), respectively. Each additional co-morbid-
ity and physician visit was associated with about 1.3% and 0.1%
decrease in adherence (p < 0.05), respectively.analysis.
Predictor variable Medication possession
ratio (natural log)
estimated coefﬁcient
(standard error)
95% Conﬁdence
interval of
estimated
coefﬁcient
Age group: 45–64 years 0.125 (0.009)a [0.106–0.143]
Age group: 65+ years 0.134 (0.018)a [0.096–0.171]
Males 0.02 (0.008)a [0.003 to 0.038]
African Americans 0.051 (0.008)a [0.067 to 0.034]
Hispanics 0.111 (0.041)a [0.192 to 0.029]
Others 0.046 (0.011)a [0.069–0.023]
High healthcare costs in
year 1 (>$16,423)
0.042 (0.009)a [0.023–0.061]
TZD 0.024 (0.008)a [0.008–0.04]
Metformin 0.345 (0.01)a [0.366 to 0.324]
Number of co morbidities 0.013 (0.002)a [0.018 to 0.009]
Number of physician visits 0.001 (0.0002)a [0.001 to 0.0007]
Constant 0.552 (0.012) [0.527–0.576]
Reference group: female gender, white race, sulfonylureas, <$16,423 costs in year 1.
a Indicates signiﬁcance at the 0.05 level for a t test examining whether beta = 0.4. Discussion
The study assessed the medication adherence in the North Car-
olina Medicaid program participants aged 18–65+ years suffering
from type-2 diabetes. When drug usage was examined across age
groups, 65+ patients showed maximum usage of TZD since these
people might have more severe form of the disease compared to
the other age groups. TZDs are used only when the disease pro-
gresses to a more severe stage and sulphonylurea alone cannot
manage the disease. Patients aged 18–44 years showed a maxi-
mum use of sulphonylurea and metformin. It may be that most
of them could no longer control their diabetes with exercise and
diet alone, and had recently switched to medications, thereby
using sulphonylurea for treatment in the initial stages. Also, if pa-
tients were obese then metformin might be favorable since re-
search has shown that it works best in obese patients agedTable 1
Descriptive characteristics of the study population (comparison of age groups 18–44 year
Variable Age group: 18–44 years (n = 681) mean
(standard deviation)
A
(s
Baseline characteristics male gender
(%)
23.49 2
Whites (%) 35.09 3
African Americans(%) 55.80 4
Hispanics (%) 0.73 0
Others (%) 8.37 1
Metformin (%) 7.63 6
Sulphonylurea (%) 42.87 3
TZD (%) 49.48 5
Total healthcare costs in year 1 ($) 8588.54 (15015.29) 9
No of co morbidities 1.35 (1.49) 2
No of physician visits 26.51 (21.15) 2
Study outcome adherence rate to new
medication (year 2)
0.46 (0.3) 0
Adherence rate of 0.58 for age group 45–64 years is same as adherence rate of 58%.below 60 years. Also, metformin is a comparatively cheaper drug,
and might lead to weight loss [8,9]. The majority of patients in
all age groups were African Americans. Previous studies have
shown that African Americans have a lower SES compared to
whites, hence it is justiﬁed that they are mostly enrolled in
Medicaid [3,6].
In multiple regression analysis, a signiﬁcant association was
found between age, medication therapy and medication adher-
ence. Comparatively, superior adherence to TZDs was seen in pa-
tients aged 18 and above due to a high risk for complications
arising out of their poverty status [10].
Due to the retrospective nature of the study, actual medication
intake was not observed. Medication adherence was used as a
proxy to measure medication taking behavior. Prescription reﬁlled
was assumed as prescription taken. Medication switching and
combination were not captured by the medication possession ra-
tio. Procured medication records at the time of discharge from hos-
pitals were not covered in the study. The observational nature of
the study does not permit causal inferences. There was limited
generalizability due to the selection of a pre deﬁned group. Infor-
mation on Hba1c level, Body Mass index, duration of diabetes
and therapy related factors like dosing, complexity of regimen
and desire for quicker results could not be obtained in the study
[9,12]. Total healthcare costs were used as a proxy to assess the
severity of the disease [3,6].s versus 45–64 years versus 65+ years).
ge group: 45–64 years (n = 2327) mean
tandard deviation)
Age group: 65+ years (n = 161) mean
(standard deviation)
6.64 24.22
5.88 33.54
6.06 46.58
.51 0.62
7.53 19.25
.66 5.59
6.22 27.32
7.11 67.08
480.18 (14174.72) 7891.39 (11176.03)
.48 (1.91) 2.35 (1.93)
8.03 (21.80) 29.39 (24.75)
.58 (0.32) 0.59 (0.33)
124 I. Patel et al. / International Journal of Diabetes Mellitus 2 (2010) 122–1245. Conclusion
The side effects associated with the medication, age progres-
sion, knowledge and beliefs and understanding of the complex
drug regimens by the elderly might affect medication adherence
in ways which are unclear and need to be researched further
[10,8]. Understanding the predictors of adherence will help in the
development of medication management therapies which might
help reduce healthcare costs and the disease burden associated
with elderly patients [10,11].
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